Assembly Biosciences, Inc. (ASMB)

Compare

8.71

-0.60

(-6.44%)

At close: April 4 at 4:00:03 PM EDT

8.70

-0.01

(-0.11%)

After hours: April 4 at 7:15:57 PM EDT

Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock?

Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 10 days ago

ASMB
-6.44%
Assembly Biosciences Full Year 2024 Earnings: Beats Expectations

Assembly Biosciences ( NASDAQ:ASMB ) Full Year 2024 Results Key Financial Results Revenue: US$28.5m (up 298% from FY...

Simply Wall St. 14 days ago

ASMB
-6.44%
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – – Interim Phase 1b proof-of-concept data, including initial efficacy measures, anticipated in fall 2025 for ABI-5366 and ABI-1179, long-acting helicase-primase inhibitor candidates for recurrent genital herpes – SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative th

GlobeNewswire 16 days ago

ASMB
-6.44%
Assembly Biosciences Insiders Placed Bullish Bets Worth US$679.4k

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Simply Wall St. 17 days ago

ASMB
-6.44%
Is Assembly Biosciences, Inc. (ASMB) Among Stocks With At Least $20 Million In Insider Spending Recently?

We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are going to take a look at where Assembly Biosciences, Inc. (NASDAQ:ASMB) stands against other stocks with at least $20 million in insider spending recently. As the stock market navigates a complex environment shaped […]

Insider Monkey last month

ASMB
-6.44%
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokinetic measures – SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first part

GlobeNewswire last month

ASMB
-6.44%
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

– ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose – – Assembly Bio to move ABI-1179 directly into Phase 1b portion of the ongoing Phase 1a/b study in participants with recurrent genital herpes – – Phase 1b to run concurrently with ongoing Phase 1b study for ABI-5366, with interim data for both candidates anticipated in fall 2025 – SOUTH SAN FRANCIS

GlobeNewswire last month

ASMB
-6.44%
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – – In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity with a mean reduction of 2.9 log IU/mL in plasma HBV DNA over 28 days of treatment – – Enrollment in final cohort of 400 mg ongoing with data anticipated in 1H 2025 – SOUTH SAN FRANCISCO, Calif., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company devel

GlobeNewswire 3 months ago

ASMB
-6.44%
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs

—Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending cash runway to mid-2026— —Additional equity investment raises Gilead’s ownership stake in Assembly Bio to 29.9%— –Funding supports pipeline progress, including amendment to accelerate clinical development of Assembly Bio’s novel small molecule hepatitis D virus candidate ABI-6250— SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Assembly B

GlobeNewswire 3 months ago

ASMB
-6.44%
Bearish: Analysts Just Cut Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue and EPS estimates

One thing we could say about the analysts on Assembly Biosciences, Inc. ( NASDAQ:ASMB ) - they aren't optimistic...

Simply Wall St. 4 months ago

ASMB
-6.44%
Assembly Biosciences: Q3 Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. AP) — Assembly Biosciences Inc. ASMB) on Thursday reported a loss of $9.6 million in its third quarter.

Associated Press Finance 4 months ago

ASMB
-6.44%
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates

Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and once-monthly oral dosing First participants dosed in Phase 1b trial evaluating ABI-5366 in individuals with recurrent genital herpes with interim data expected in first half of 2025Phase 1b trial for ABI-4334, a next-generation highly potent capsid assembly modulator candidate, ongoing in participants with chronic HBV

GlobeNewswire 4 months ago

ASMB
-6.44%
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

Here is how Adma Biologics (ADMA) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.

Zacks 5 months ago

ADMA

ASMB
-6.44%
Assembly Biosciences' Investigational Herpes Treatment Shows Safety In Healthy Participants (UPDATED)

Editor’s Note: The title of the story has been updated to reflect the accuracy of the data Assembly Biosciences, Inc. (NASDAQ:ASMB) released interim pharmacokinetic (PK) and safety results from healthy participants in the Phase 1a portion of its ongoing Phase 1a/b study of ABI-5366, an investigational long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidate for recurrent genital herpes. Due to its extended PK profile, ABI-5366 was well-tolerated and showed a favorable safety p

Benzinga 6 months ago

ASMB
-6.44%
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366

– ABI-5366 was well-tolerated, with a favorable safety profile observed with exposure of up to 70 days – – Half-life of approximately 20 days supports once-weekly or once-monthly oral dosing; both dosing schedules will be explored in the Phase 1b portion of the study – – Screening of participants with recurrent genital herpes is now underway for Phase 1b – SOUTH SAN FRANCISCO, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing

GlobeNewswire 6 months ago

ASMB
-6.44%
Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year?

Here is how Assembly Biosciences (ASMB) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Zacks 6 months ago

ASMB
-6.44%
ADMA
Is Sensus Healthcare (SRTS) Stock Outpacing Its Medical Peers This Year?

Here is how Sensus Healthcare, Inc. (SRTS) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.

Zacks 7 months ago

SRTS

ASMB
-6.44%
Individual investors in Assembly Biosciences, Inc. (NASDAQ:ASMB) are its biggest bettors, and their bets paid off as stock gained 14% last week

Key Insights The considerable ownership by individual investors in Assembly Biosciences indicates that they...

Simply Wall St. 7 months ago

ASMB
-6.44%
Assembly Biosciences: Q2 Earnings Snapshot

ASMB) on Thursday reported a loss of $11.2 million in its second quarter. The South San Francisco, California-based company said it had a loss of $1.98 per share. The biotech drug developer posted revenue of $8.5 million in the period.

Associated Press Finance 7 months ago

ASMB
-6.44%
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates

Dosing initiated in healthy participants in Phase 1a/b trial for ABI-5366 targeting recurrent genital herpes, with interim Phase 1a first-in-human data expected in Q3 2024 and interim Phase 1b data in participants with recurrent genital herpes expected in first half of 2025Dosing initiated in Phase 1b trial for ABI-4334 in participants with chronic HBV infection, with interim Phase 1b data expected by end of yearTwo additional pipeline candidates, ABI-1179 and ABI-6250, anticipated to enter clin

GlobeNewswire 7 months ago

ASMB
-6.44%

Performance Overview

Return	ASMB	S&P 500 (^GSPC)
YTD	-44.80%	-13.73%
1-Year	-36.14%	-1.42%
3-Year	-65.76%	+10.72%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Assembly Biosciences, Inc. (ASMB)

Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock?

Assembly Biosciences Full Year 2024 Earnings: Beats Expectations

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Assembly Biosciences Insiders Placed Bullish Bets Worth US$679.4k

Is Assembly Biosciences, Inc. (ASMB) Among Stocks With At Least $20 Million In Insider Spending Recently?

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs

Bearish: Analysts Just Cut Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue and EPS estimates

Assembly Biosciences: Q3 Earnings Snapshot

Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates

Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

Assembly Biosciences' Investigational Herpes Treatment Shows Safety In Healthy Participants (UPDATED)

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366

Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year?

Is Sensus Healthcare (SRTS) Stock Outpacing Its Medical Peers This Year?

Individual investors in Assembly Biosciences, Inc. (NASDAQ:ASMB) are its biggest bettors, and their bets paid off as stock gained 14% last week

Assembly Biosciences: Q2 Earnings Snapshot

Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates

Performance Overview